Please login to the form below

Not currently logged in
Email:
Password:

idelalisib

This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

FDA approves Gilead drug in three blood cancers

FDA approves Gilead drug in three blood cancers

The FDA recommended the use of Zydelig ( idelalisib) in combination with Roche's Rituxan ( rituximab) to treat patients with relapsed chronic lymphocytic leukaemia.

Latest news

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Clarity of vision, insight and a thought-through strategic approach are our tools for delivering solutions that benefit our clients and...

Latest intelligence

Online Physician Communities
Global cancer conference inspires M3’s largest highlights programme
ASCO initiative spans 16 European countries and five specialties...
Online Physician Communities
M3 improves personalisation of pharma engagement with doctors
Launches new messaging service on Doctors.net.uk...
Digital Futures 2014 slide deck
Full slides, including survey data, from PMLiVE's digital pharma marketing online event...